Competition
Competition — MetLife, Inc. (MET)
Competitive Bottom Line
MetLife has a real but narrow moat in two specific arenas — U.S. Group Benefits (~23% share, top-3 with Cigna/NYL and Unum) and U.S. pension risk transfer (PRT, co-leader with Prudential) — wrapped around three businesses where its position is good-not-dominant: Asia (top-tier foreign player but behind domestic giants), Latin America (top-3 Mexico/Chile, but exposed), and an asset manager (MIM, $736B Total AUM at Q1 2026) that is sub-scale next to PGIM (~$1.6T) and the alt-credit majors. The single competitor that matters most is Prudential (PRU) — the only direct comp that lines up segment-by-segment in retirement, Asia, and asset management — currently winning on price-to-book (1.21× vs MET 1.82×) but trailing on ROE (11.0% vs 12.1%) and capital-return ($4.4B at MET vs ~$3.0B at PRU). The market is mispricing the durability of MET's Group Benefits oligopoly and the optionality on MIM scaling toward $1T, while correctly worrying about (1) PE-backed annuity platforms (Athene/Apollo, Brookfield, Global Atlantic/KKR) compressing PRT spreads and (2) mutual-company peers (Northwestern Mutual, MassMutual, NY Life) underpricing because they have no ROE constraint.
The frame: MET is not a single-product franchise. Its moat is a portfolio of three different competitive positions — group-benefits oligopoly, PRT duopoly with PRU, and Asia/LatAm scale — bundled with a sub-scale fee business that has option value. Judging the moat means judging each leg separately, not averaging them.
The Right Peer Set
The peer set is the five U.S.-listed life/multi-line insurers with the most product overlap to MET's reporting segments. Each has full FY2005–FY2025 financial history under U.S. GAAP, which keeps ratio comparisons clean.
All values FY2025; valuations as of 2025-12-31. AFL and UNM enterprise value equals market cap because each carries near-zero net debt at year-end. Source: company filings.
What the chart says. Three things stand out. First, AFL gets the highest P/B (1.94×) for a similar ROE (13%) to MET (12%) — the market pays more for capital-light underwriting than for leveraged spread. Second, LNC at 0.78× book is the cautionary tale: a 12% headline ROE the market does not believe (FY24 ROE was 43% on a one-time reserve release; underlying earnings power is much lower). Third, MET sits between PRU and AFL on P/B but below AFL on ROE — credited for diversification but not yet for the 15-17% adjusted ROE management has guided to in the New Frontier 2026-2029 plan.
Why these five and not others. Brighthouse (BHF) is a MET-spinoff annuity run-off, not an economic substitute; AIG is now P&C-heavy after Corebridge separation; Corebridge (CRBG) only has three years of public history; Globe Life (GL) is mass-market term life only; RGA is a life reinsurer (counterparty, not substitute); Manulife/Sun Life report under IFRS/CAD which breaks ratio comparability. Equitable, Voya, and Jackson are viable secondary peers, covered implicitly through the "PE-backed annuity" threat lens below.
Where The Company Wins
1. U.S. Group Benefits scale — a top-3 oligopoly position with structural pricing power
MetLife is the #1 or #2 group benefits provider in the United States with an estimated ~23% market share in 2023 — a position built on four decades of relationships with the largest U.S. employers and a sales force segmented by employer size (jumbo, large, mid-market, small). The 10-K is direct: "We have built a leading position in the U.S. group insurance market through long-standing relationships with many of the largest employers in the U.S." Group benefits reprices annually, which means margin compression from a bad mortality year (2020 pandemic) is recovered within 12-18 months — and group adjusted earnings did exactly that, growing +7.3% YoY in FY2025 to $1.69B. Unum (the pure group peer) generated only $0.74B of net income on a 6.7% ROE for the same product set, a clean read on what scale plus diversification adds: roughly 5 percentage points of ROE versus a sub-scale single-line group competitor.
2. PRT co-leadership — a regulator- and capital-gated duopoly with PRU
MetLife and Prudential are the two dominant pension risk transfer providers in the U.S., with roughly 100 years of history apiece. RIS adjusted earnings of $1.67B in FY2025 sit on a $300B+ liability stack, and the segment has executed multiple jumbo deals ($14B+ class) in the last cycle. The economics work because PRT is capital- and regulator-gated: very few players have the RBC headroom, ALM expertise, and credit ratings to bid on jumbo deals. PE-backed reinsurers target this pool, but MET's installed base of ~915,000 retirees and ~$5.5B/year of benefit payments is the kind of administrative scale newcomers cannot replicate quickly.
3. Asia franchise — uniquely broad foreign presence, with Japan as the anchor
MetLife operates in nine Asian jurisdictions, with Japan as the largest, and grew Asia adjusted earnings +12.1% YoY to $1.70B in FY2025 — the fastest-growing segment by dollars after MIM. The right peer comparison is AFL Japan, which generated 53% of AFL's adjusted revenues (FY2025) and 76% of AFL's total assets. AFL is bigger in Japan supplemental but more concentrated in it; MET is broader across nine markets and product types. PRU's Japan business is comparable in scale to MET's, but PRU does not have MET's Korea/India/China-JV footprint. This is the leg most exposed to FX translation, but also the leg with the most growth runway.
4. Diversification — the lowest segment concentration in the public peer set
Values are management-disclosed for AFL (10-K explicit) and approximate for others. MET's even mix across Group Benefits ($1.69B), RIS ($1.67B), Asia ($1.70B), and LatAm ($798M) is unmatched in the listed peer set.
The diversification benefit is real and measurable: MET's GAAP earnings volatility (standard deviation 2021-2025) is lower than PRU's and LNC's, even though MET's spread-business exposure is similar. PRU lost money in FY2022 (ROE -3.4%) on assumption updates; LNC lost money in FY2023 (-12.5% ROE) on VA reserve issues. MET's worst recent year (FY2023, 5.3% ROE) is a milder dip, and its FY2024 recovery (15.3% ROE) was sharper than peers. An investor pays a slightly higher P/B for that smoother ride — and that is the trade.
MET's line (the smoothest) sits right around the 12% mid-band for the 5-year window; AFL is highest and most stable on the underwriting model; LNC and PFG show the through-cycle volatility of the heavy-spread peers.
Where Competitors Are Better
1. AFL crushes MET on net margin and capital efficiency — and the market notices
AFL's FY2025 net margin was 21.2% on $17.2B of revenue versus MET's 4.4% on $77.1B, and AFL runs at 3.95× assets/equity versus MET's 26×. The two business models are genuinely different (AFL is supplemental underwriting; MET is leveraged spread + scale), but the market still pays AFL 1.94× book versus MET's 1.82× despite a smaller cap-light franchise. The actionable read: MET cannot grow into AFL's margin profile without giving up its general-account franchise — the spread engine and the heavy-leverage book are the same balance sheet. MET's path to a higher P/B runs through MIM scale (capital-light fee income), not through margin expansion in the insurance segments.
2. PRU's PGIM is a meaningfully larger and more diversified asset manager than MIM
MIM is roughly 45-46% of PGIM's AUM and earns less in fees per dollar (smaller alt-credit and equity exposure). The New Frontier $1T target would close the gap to roughly 60% of PGIM's current scale — still meaningfully smaller, and reaching $1T requires the PineBridge contribution (closed Dec 30, 2025; helped lift MET Total AUM 22% YoY to $736B at Q1 2026) plus consistent organic flow above industry rates. Alongside private-market asset managers — Apollo (~$840B AUM total, with the Athene insurance liability arm), Brookfield ($1T+), KKR/Global Atlantic ($600B+) — MIM is sub-scale on alt-credit, the highest-fee, fastest-growing slice of institutional AUM.
3. PRU and PFG sell at meaningfully cheaper book multiples — value rotation risk
For a value-style investor seeking the U.S. life/retirement composite at the cheapest possible price-to-book, PRU at 1.21× is the obvious entry point — closer to its long-term mean and well below MET's 1.82×. MET trades at a 50%+ premium to PRU on book with only +110 bp of ROE advantage to justify it. That premium is fragile if the New Frontier ROE target slips.
4. PE-backed reinsurance platforms can underprice MET in retail annuities and bolt-on PRT blocks
The most economically dangerous competitive shift in the last decade is the rise of Athene/Apollo, Brookfield Reinsurance, Global Atlantic/KKR, and Resolution Life — alternative-credit-funded balance sheets that source higher-yielding private credit and structured assets, then pass a portion of that yield through as higher annuity crediting rates. In retail fixed annuities and structured settlements, this has compressed spreads industry-wide. In bolt-on PRT (smaller deals, partial-block reinsurance), Athene in particular has scaled quickly. MET's RIS spread of roughly 200 bps on jumbo PRT is reasonably defended by capital and ratings barriers, but the retail annuity portion of MetLife Holdings is genuinely contested and the asset sourcing for the general account (where MIM does the heavy lifting) is competing with managers that fund insurance liabilities at the same time. This is the single competitive trend most likely to compress MET's spread economics over a 5-10 year window.
Threat Map
The threat that should keep an investor up at night: PE-backed annuity/PRT platforms. Spread compression on the general account is the slow-burn risk that, if it plays out, would lower MET's normalized adjusted ROE by 100-200 bps over a 5-year window — directly hitting the bull case that depends on closing the gap to the 15-17% New Frontier target. The mutual-company structural ceiling is permanent but already priced in; the PE risk is dynamic and not yet fully priced.
Moat Watchpoints
The single number to watch: the gap between MET's reported adjusted ROE (~12% in FY25) and the 15-17% New Frontier target. Closing that gap is the entire bull case; failing to close it is the entire bear case. If you are tracking one chart on this name, track adjusted ROE quarterly against the target band.